NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
Clinical Trials
36 trialsNCT04964960 2025-10-31
Pembro+Chemo in Brain Mets
University of Kentucky
Phase 2 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02093962 2025-05-16
Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer
ImmunoGenesis
Phase 2 Terminated
NCT06094296 2025-04-16
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 2 Terminated
NCT04512430 2025-04-02
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Phase 2 Terminated
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT05241873 2025-02-10
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04364048 2024-12-20
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT05583188 2024-07-19
VIGOR
Galvanize Therapeutics, Inc.
Phase 4 Terminated
NCT04971187 2023-08-01
Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05153408 2023-06-18
(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
Blueprint Medicines Corporation
Phase 1 Terminated
NCT04372927 2023-06-13
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
University of Washington
Phase 2 Terminated
NCT03041181 2022-07-11
Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00402883 2021-11-09
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00438204 2021-04-13
Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00794417 2020-12-10
A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT00538681 2020-11-05
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
Eli Lilly and Company
Phase 2 Terminated
NCT00923273 2019-11-26
Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01646125 2019-07-24
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Novartis
Phase 2 Terminated
NCT03348904 2019-06-13
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Phase 3 Terminated
NCT01041781 2018-07-23
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00470548 2018-01-10
Abraxane and Alimta in Advanced Solid Tumors
University of California, Davis
Phase 1/2 Terminated
NCT00280748 2017-06-23
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT00129974 2017-06-16
Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
Tufts Medical Center
Phase 2 Terminated
NCT02087241 2017-03-29
Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer
AstraZeneca
Phase 2 Terminated
NCT00863512 2017-03-27
Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00612677 2017-03-23
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Terminated
NCT00520845 2017-03-20
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT00391586 2015-08-17
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01356368 2014-01-22
Customizing
National Guard Health Affairs
Phase 2 Terminated
NCT00365183 2013-10-31
Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer
Pharmacyclics LLC.
Phase 2 Terminated
NCT00265785 2012-11-01
S0526: Pemetrexed Disodium in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 2 Terminated
NCT00389688 2012-07-18
Pemetrexed Disodium and Cisplatin Before or After Surgery in Treating Patients With Stage IB or Stage II Non-Small Cell Lung Cancer That Can be Removed by Surgery
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Terminated
NCT00356525 2010-08-17
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
Eli Lilly and Company
Phase 2 Terminated
NCT00290017 2007-06-08
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Point Therapeutics
Phase 3 Terminated